Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Firdapse re-catalyzes pricing debate

A decision by Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) to charge $375,000 a year for Firdapse amifampridine phosphate, a drug that was previously available for free, has re-catalyzed debate about the U.S. government’s drug exclusivity policies.

The company announced the wholesale acquisition cost for the drug, which late last month became the first drug approved by FDA to treat Lambert-Eaton myasthenic syndrome (LEMS), on a conference call on Thursday.

The Firdapse case illustrates a public policy

Read the full 734 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE